Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).
52 Week High
52 Week Low
Data Provided by Refinitiv. Minimum 15 minutes delayed.
- GC Pharma to lead development and commercialization in South Korea - Mirum seeks to expand global availability of maralixibat in rare liver diseases FOSTER CITY, Calif. & YONGIN, South Korea --(BUSINESS WIRE)--Jul. 26, 2021-- Mirum Pharmaceuticals, Inc.
FOSTER CITY, Calif. --(BUSINESS WIRE)--Jul. 12, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on July 12, 2021 , the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 146,400 shares of common stock to
FOSTER CITY, Calif. --(BUSINESS WIRE)--Jun. 24, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leader in rare liver disease, today announced that it will participate in Piper Sandler’s Virtual European Association for the Study of the Liver (EASL) Takeaway Day on Monday, June 28, 2021 , at
- Data from five years of treatment with maralixibat reinforces safety and tolerability in patients with Alagille syndrome. - Intrahepatic cholestasis of pregnancy patient-reported data demonstrates significant burden of disease and underscores urgent need for new treatment options.